EP1910323A1 - Process for preparing 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine - Google Patents

Process for preparing 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine

Info

Publication number
EP1910323A1
EP1910323A1 EP06764080A EP06764080A EP1910323A1 EP 1910323 A1 EP1910323 A1 EP 1910323A1 EP 06764080 A EP06764080 A EP 06764080A EP 06764080 A EP06764080 A EP 06764080A EP 1910323 A1 EP1910323 A1 EP 1910323A1
Authority
EP
European Patent Office
Prior art keywords
chlorophenyl
propyl
propoxy
piperidine
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06764080A
Other languages
German (de)
French (fr)
Inventor
Juan SALLARÉS
Inés PETSCHEN
Xavier Camps
Holger Stark
Walter Schunack
Marc Capet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioprojet SC
Original Assignee
Ferrer Internacional SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Internacional SA filed Critical Ferrer Internacional SA
Priority to EP06764080A priority Critical patent/EP1910323A1/en
Publication of EP1910323A1 publication Critical patent/EP1910323A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

  • the present invention relates to a process for preparing 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine .
  • EP 982300 discloses the preparation of said compound in a heterogeneous phase, which comprises the use of crown ether phase transfer catalysts, resulting in an inappropriate industrial process because of its high cost and toxicity.
  • compound (I) obtained according to the prior art method yields an improper purity profile to be used directly in the preparation of pharmaceutically acceptable salts thereof.
  • the present invention discloses a process for preparing 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine (I) which is more efficient than the process reported in the prior art.
  • a sufficiently pure free base compound is obtained, which can then be used directly in the manufacturing of pharmacologically acceptable salts thereof, without any isolation or subsequent purification steps .
  • the present invention also circumvents phase transfer catalysts thus providing a more convenient industrial process. Also, operating temperatures in the process of the present invention are lower than in the heterogeneous phase reaction disclosed in the prior art. In fact, in the present invention, reaction occurs at room temperature, i.e. 20-25°C, in contrast to 80-110°C needed in the prior art process. Such new smoother reaction conditions generate less impurities than those appearing in processes already described.
  • the present invention comprises a process for the manufacture of 1- [3- [3- (4-chlorophenyl) propoxy] propyl] - piperidine (I) , which involves the formation of 3- piperidinopropanol (II) sodium salt in an aprotic polar solvent and subsequent reaction with 3- (4- chlorophenyl) propyl mesylate (III), according to Scheme 1.
  • the aprotic polar solvent is selected from N,N-dimethylformamide, N, N- dimethylacetamide, l-methyl-2-pyrrolidone, l-methyl-2- piperidone, 1, 3-dimethyl-2-imidazolidinone, and the like, and mixtures thereof.
  • molecular equivalents of both sodium hydride and 3- (4- chlorophenyl) propyl mesylate (III) are used in excess to the molecular equivalents of 3-piperidinopropanol (II) .
  • the quantity of sodium hydride is from about 1.1 to about 2.0 molecular equivalents, more preferably from about 1.4 to about 1.7.
  • 3- (4- chlorophenyl) propyl mesylate (III) the quantity thereof is from about 1.1 to about 2.0 molecular equivalents, preferably from about 1.2 to about 1.5. Accordingly, the excess of sodium hydride assures that 3- piperidinopropanol (II) remains as its reactive sodium salt specie.
  • 3- (4-chlorophenyl) propyl mesylate (III) should be in excess because of its chemical lability.
  • reaction of the sodium salt of compound (II) with compound (III) is performed at room temperature (i.e. 20-25°C) .
  • the limiting reactant 3-piperidinopropanol (II) is fully converted, thus providing 1- [3- [3- (4-chlorophenyl) propoxy] propyl] - piperidine (I) as the unique nitrogen-bearing compound obtained.
  • 3-piperidinopropanol (1 Kg, 6.98 mol) was dissolved in anhydrous N,N-dimethylacetamide (8.8 L) under a nitrogen atmosphere. Then sodium hydride 60% (0.449 Kg, 11.23 mol) was slowly added. The mixture was heated at 50°C for 1 hour with stirring. Then the mixture was cooled at 25°C and a solution of 3- (4-chlorophenyl) propyl mesylate (2.08 Kg, 8.36 mol) in anhydrous N,N-dimethylacetamide (3.5 L) was added for 2 hours . The mixture was stirred for 7 hours at 22°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a process for preparing 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine (I) by reaction of 3-piperidinopropanol (II) with sodium hydride in an aprotic polar solvent and further reaction with 3- (4-chlorophenyl) propyl mesylate (III).

Description

Process for preparing 1- [3- [3- (4-chlorophenyl)propoxy] propyl] -piperidine
Field of the invention
The present invention relates to a process for preparing 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine .
Background of the invention
1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine belongs to the pharmacological class of ligands of histamine H3 receptors and has the structural formula
(D :
The specification EP 982300 discloses the preparation of said compound in a heterogeneous phase, which comprises the use of crown ether phase transfer catalysts, resulting in an inappropriate industrial process because of its high cost and toxicity.
Moreover, compound (I) obtained according to the prior art method yields an improper purity profile to be used directly in the preparation of pharmaceutically acceptable salts thereof.
The purification of compound (I) obtained according to the prior art process would require an additional column chromatography and/or a molecular distillation process. Column chromatography techniques are not widely used in manufacturing processes, partly because of the large quantities of solvents needed, which may result in environmental problems . On the other hand, fractioned distillation of compound (I) is not convenient because of its high boiling point (180°C / 0.01 mmHg) . This fact forces to use a molecular distillation equipment, which limits its industrial feasibility.
Description of the invention
The present invention discloses a process for preparing 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine (I) which is more efficient than the process reported in the prior art. Thus, by using reaction conditions in a homogeneous phase, a sufficiently pure free base compound is obtained, which can then be used directly in the manufacturing of pharmacologically acceptable salts thereof, without any isolation or subsequent purification steps .
The present invention also circumvents phase transfer catalysts thus providing a more convenient industrial process. Also, operating temperatures in the process of the present invention are lower than in the heterogeneous phase reaction disclosed in the prior art. In fact, in the present invention, reaction occurs at room temperature, i.e. 20-25°C, in contrast to 80-110°C needed in the prior art process. Such new smoother reaction conditions generate less impurities than those appearing in processes already described.
The present invention comprises a process for the manufacture of 1- [3- [3- (4-chlorophenyl) propoxy] propyl] - piperidine (I) , which involves the formation of 3- piperidinopropanol (II) sodium salt in an aprotic polar solvent and subsequent reaction with 3- (4- chlorophenyl) propyl mesylate (III), according to Scheme 1.
Scheme 1
In another embodiment, the aprotic polar solvent is selected from N,N-dimethylformamide, N, N- dimethylacetamide, l-methyl-2-pyrrolidone, l-methyl-2- piperidone, 1, 3-dimethyl-2-imidazolidinone, and the like, and mixtures thereof.
In another embodiment of the present invention process, molecular equivalents of both sodium hydride and 3- (4- chlorophenyl) propyl mesylate (III) are used in excess to the molecular equivalents of 3-piperidinopropanol (II) . Thus, the quantity of sodium hydride is from about 1.1 to about 2.0 molecular equivalents, more preferably from about 1.4 to about 1.7. Regarding 3- (4- chlorophenyl) propyl mesylate (III), the quantity thereof is from about 1.1 to about 2.0 molecular equivalents, preferably from about 1.2 to about 1.5. Accordingly, the excess of sodium hydride assures that 3- piperidinopropanol (II) remains as its reactive sodium salt specie. Likewise, 3- (4-chlorophenyl) propyl mesylate (III) should be in excess because of its chemical lability.
In another embodiment, the reaction of the sodium salt of compound (II) with compound (III) is performed at room temperature (i.e. 20-25°C) . In the process of the present invention, the limiting reactant 3-piperidinopropanol (II) is fully converted, thus providing 1- [3- [3- (4-chlorophenyl) propoxy] propyl] - piperidine (I) as the unique nitrogen-bearing compound obtained.
Further washes of the aqueous phase containing the formed salt of 1- [3- [3- (4-chlorophenyl) propoxy] propyl] - piperidine (I) with an organic solvent removes all non nitrogen by-products, yielding a product (I) with a quality good enough to be used in subsequent process steps without any kind of purification.
Example 1: 1- [3- [3- (4-chlorophenyl) propoxy] propyl] - piperidine (I)
3-piperidinopropanol (1 Kg, 6.98 mol) was dissolved in anhydrous N,N-dimethylacetamide (8.8 L) under a nitrogen atmosphere. Then sodium hydride 60% (0.449 Kg, 11.23 mol) was slowly added. The mixture was heated at 50°C for 1 hour with stirring. Then the mixture was cooled at 25°C and a solution of 3- (4-chlorophenyl) propyl mesylate (2.08 Kg, 8.36 mol) in anhydrous N,N-dimethylacetamide (3.5 L) was added for 2 hours . The mixture was stirred for 7 hours at 22°C. Then the mixture was cooled at 10°C and a solution of sodium chloride (1.1 Kg) in water (13.3 L) was slowly added. After extraction of the aqueous phase several times with toluene, the organic extracts were combined and extracted with HCl (7 L, 2N) . The aqueous phase was then washed with toluene (1.75 L) . The aqueous phase was treated with sodium hydroxide (6N, 2.5 L) and taken to pH 12, and then extracted twice with 7 L of toluene. The toluene extracts were washed thrice with 7 L of water. Toluene was distilled at reduced pressure to yield 1.99 Kg of 1- [3- [3- (4-chlorophenyl) propoxy] propyl] piperidine (I) as an oil. Yield 99.3%. Purity (GC) 99.2%.

Claims

1. A process for the preparation of l-[3-[3-(4- chlorophenyl) propoxy] propyl] -piperidine (I) :
which comprises reaction of 3-piperidinopropanol (II) :
HO N
π
with sodium hydride to form the sodium salt of (II) wherein the quantity of sodium hydride is from about 1.1 to about 2.0 molecular equivalents, in an aprotic polar solvent and subsequent reaction with 3- (4- chlorophenyl) propyl mesylate (III) :
III
wherein the quantity of (III) is from about 1.1 to about 2.0 molecular equivalents .
2. A process according to claim 1 wherein the quantity of sodium hydride is from about 1.4 to about 1.7 molecular equivalents.
3. A process according to claim 1 wherein the quantity of compound (III) is from about 1.2 to about 1.5 molecular equivalents .
4. A process according to claim 1 wherein the aprotic polar solvent is selected from N,N-dimethylformamide, N,N-dimethylacetamide, l-methyl-2-pyrrolidone, 1-methyl- 2-piperidone, 1, 3-dimethyl-2-imidazolidinone and mixtures thereof.
5. A process according to claim 4 wherein the aprotic polar solvent is N,N-dimethylacetamide .
6. A process according to claim 1 wherein the reaction of the sodium salt of (II) with (III) is performed at room temperature .
EP06764080A 2005-07-08 2006-07-05 Process for preparing 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine Withdrawn EP1910323A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06764080A EP1910323A1 (en) 2005-07-08 2006-07-05 Process for preparing 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05106263 2005-07-08
PCT/EP2006/063927 WO2007006708A1 (en) 2005-07-08 2006-07-05 Process for preparing 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
EP06764080A EP1910323A1 (en) 2005-07-08 2006-07-05 Process for preparing 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine

Publications (1)

Publication Number Publication Date
EP1910323A1 true EP1910323A1 (en) 2008-04-16

Family

ID=36997559

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06764080A Withdrawn EP1910323A1 (en) 2005-07-08 2006-07-05 Process for preparing 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine

Country Status (4)

Country Link
EP (1) EP1910323A1 (en)
AR (1) AR054530A1 (en)
TW (1) TWI382975B (en)
WO (1) WO2007006708A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103435575A (en) * 2013-08-06 2013-12-11 中国人民解放军军事医学科学院毒物药物研究所 Preparation method of 1-(3-(3-(4-chlorphenyl) propoxy) propyl) piperidine hydrochloride
CN104447620B (en) * 2014-11-28 2016-05-04 瑞阳制药有限公司 1-[3-[3-(4-chlorphenyl) propoxyl group] propyl group] preparation method of-piperidine hydrochlorate
EP3239138A1 (en) 2016-04-25 2017-11-01 Sandoz Ag Hydrogen fumarate salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
IT201900013941A1 (en) 2019-08-05 2021-02-05 Procos Spa PROCESS FOR THE SYNTHESIS OF PITOLISANT HCl
US11945788B2 (en) 2021-06-07 2024-04-02 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof
US11623920B2 (en) 2021-06-07 2023-04-11 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007006708A1 *

Also Published As

Publication number Publication date
WO2007006708A1 (en) 2007-01-18
TW200736238A (en) 2007-10-01
AR054530A1 (en) 2007-06-27
TWI382975B (en) 2013-01-21

Similar Documents

Publication Publication Date Title
JP5852573B2 (en) Method for producing 1-triazole-2-butanol derivative
US8884021B2 (en) Process for preparing racemic nicotine
WO2007006708A1 (en) Process for preparing 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
WO2013014478A1 (en) Reductive amination process for preparation of dronedarone using carboxyl intermediary compound
EP1937662B1 (en) Process for the preparation of duloxetine
CN117229136A (en) Preparation method of azelaic acid
JP2012526802A (en) Method for producing alkylamine derivative
US20100063292A1 (en) Process for the preparation of trifluoroethoxytoluenes.
CN115819251A (en) Preparation method of (1R) -1- [3- (difluoromethyl) -2-fluorophenyl ] ethylamine
EP1366034B1 (en) Preparation of phthalanes
KR20160027536A (en) Process for preparing an intermediate useful for the synthesis of silodosin
KR100486432B1 (en) Method for producing 5-aminomethyl-2-chloropyridines
EP3112334A1 (en) Process for manufacturing 1-cyclopropyl-naphthalenes
CN103848757B (en) Synthetic 3-(2-bromo-4,5-dimethoxy phenyl) method of propionitrile and the application in synthesis of ivabradine thereof
CN112661668A (en) N-substituted amide compound and preparation method thereof
NO147838B (en) INTERMEDIATE FOR USE IN PREPARATION OF THE HYPOTENSIVE AGENT 2- (4- (2-FUROYL) PIPERAZIN-1-YL) -4-AMINO-6,7-DIMETOXYKINAZOLINE
DE69708136T2 (en) SELECTIVE ALKYLATION OF A PHENOL COMPOUND SUBSTITUTED BY AN ALCOHOL
EP3704116B1 (en) Process for the synthesis of 2-benzhydryl-3 quinuclidinone
CN109369618B (en) Method for preparing 2-chloro-5- ((2- (nitromethylene) imidazoline-1-yl) methyl) pyridine in one pot
JP5424272B2 (en) Method for producing 9-hydroxymethyl-cyclohepta [b] pyridine-3-carboxylic acid ester derivative
KR100297802B1 (en) Method for preparing 2- (3-trifluoromethyl) anilinonicotinic acid 2- (N-morpholine) ethyl.
KR20090016201A (en) Process for preparing donepezil or its synthetic intermediate
CN118047704A (en) 1- (Carbonyl) -3- ((methylthio) methyl) cyclobutane-1-benzyl formate derivative and preparation method thereof
JP2007519660A (en) Method for producing 2- (ethoxymethyl) tropane derivative
CA2372763C (en) New process

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20080421

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOPROJET

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081102